ReviewPET clinics2015
PET/Computed Tomography in Renal, Bladder, and Testicular Cancer.
Review in PET clinics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 32 citations in OpenAlex.
- Positron Emission Tomography/Computed Tomography in Bladder Cancer: The Role of [Medicina (Kaunas, Lithuania) · 2026Review
- The role ofCancer imaging : the official publication of the International Cancer Imaging Society · 2019Article
- Article
- Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases.Current urology reports · 2018Review
- Current Concepts in the Management of Muscle Invasive Bladder Cancer.Indian journal of surgical oncology · 2017Review
- Carbon-11 and Fluorine-18 Labeled Amino Acid Tracers for Positron Emission Tomography Imaging of Tumors.Frontiers in chemistry · 2017Review
- PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study.Abdominal radiology (New York) · 2016Article
- The Place of FDG PET/CT in Renal Cell Carcinoma: Value and Limitations.Frontiers in oncology · 2016Review
- Nanotechnology and cancer: improving real-time monitoring and staging of bladder cancer with multimodal mesoporous silica nanoparticles.Cancer nanotechnologyArticle
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Imaging plays an important role in the clinical management of cancer patients. Hybrid imaging with PET/computed tomography (CT) is having a broad impact in oncology, and in recent years PET/CT is beginning to have an impact in urooncology. In both bladder and renal cancers, there is a need to study the efficacy of other tracers than F-18 fluorodeoxyglucose (FDG), particularly tracers with limited renal excretion. Thus, new tracers are being introduced. This review focuses on the clinical role of FDG and other PET agents in renal, bladder, and testicular cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.